Focus on Lipids Care

Back to articles

Edema, Cardiovascular Concerns May Limit Use of Muraglitazar

KEY POINT

An agent that can positively affect glycemic control and lipid levels is nearing FDA approval, but concerns over cardiovascular problems and edema are expected to mute clinician excitement about—and use of— muraglitazar (Pargluva—Bristol-Myers Squibb; Merck).

SOURCES

 

Kang P. Bristol-Myers’ Pargluva has ‘less-favorable outlook.’ Forbes.

Food and Drug Administration. FDA advisory committee briefing document: Pargluva (muraglitazar, BMS-298585).

Recent Articles